Virus Genes

, Volume 44, Issue 3, pp 374–381

Development of a drug assay system with hepatitis C virus genome derived from a patient with acute hepatitis C

  • Kyoko Mori
  • Youki Ueda
  • Yasuo Ariumi
  • Hiromichi Dansako
  • Masanori Ikeda
  • Nobuyuki Kato
Article

DOI: 10.1007/s11262-012-0712-2

Cite this article as:
Mori, K., Ueda, Y., Ariumi, Y. et al. Virus Genes (2012) 44: 374. doi:10.1007/s11262-012-0712-2

Abstract

We developed a new cell culture drug assay system (AH1R), in which genome-length hepatitis C virus (HCV) RNA (AH1 strain of genotype 1b derived from a patient with acute hepatitis C) efficiently replicates. By comparing the AH1R system with the OR6 assay system that we developed previously (O strain of genotype 1b derived from an HCV-positive blood donor), we demonstrated that the anti-HCV profiles of reagents including interferon-γ and cyclosporine A significantly differed between these assay systems. Furthermore, we found unexpectedly that rolipram, an anti-inflammatory drug, showed anti-HCV activity in the AH1R assay but not in the OR6 assay, suggesting that the anti-HCV activity of rolipram differs depending on the HCV strain. Taken together, these results suggest that the AH1R assay system is useful for the objective evaluation of anti-HCV reagents and for the discovery of different classes of anti-HCV reagents.

Keywords

HCVAcute hepatitis CAnti-HCV drug assay systemAnti-HCV activity of rolipram

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Kyoko Mori
    • 1
  • Youki Ueda
    • 1
  • Yasuo Ariumi
    • 1
  • Hiromichi Dansako
    • 1
  • Masanori Ikeda
    • 1
  • Nobuyuki Kato
    • 1
  1. 1.Department of Tumor VirologyOkayama University Graduate School of Medicine, Dentistry, and Pharmaceutical SciencesOkayamaJapan